Fundraising Fox

Bicara Therapeutics

NASDAQ: BCAX

Incorporated in Delaware · 12 known investors

Find your way into Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors. The company's lead program, ficerafusp alfa, fuses an EGFR-directed antibody with a TGF-β ligand trap to simultaneously inhibit tumor cell growth and suppress immunosuppressive signaling in the tumor microenvironment, with initial development focused on head and neck squamous cell carcinoma.

Founders & leadership

IHIvan Hyep
Ivan HyepinAdvisor
LM
Lara MeisnerinChief Legal Officer2023–2026
DRDavid Raben
David RabeninCMO, Bicara Therapeutics2023–2026Dr. David Raben is a board-certified radiation oncologist with over 25 years of academic translational oncology experience and more than four years in pharmaceutical development, most recently serving as vice president of global product development at Amgen where he led the anti-DLL3 program in neuroendocrine cancers, and previously as vice president of clinical development oncology at Genentech focused on precision medicine and immunotherapy in head and neck and thoracic cancers. He holds a B.A. from Duke University and an M.D. from Wake Forest University, completed radiation oncology residency at Johns Hopkins Hospital, and spent over 20 years as a professor at the University of Colorado Cancer Center with expertise in EGFR signaling, DNA damage repair, TGF-β biology, and checkpoint inhibition.

Investors · 12

Aisling CapitalNew York
Eight Roads VenturesMumbai · $5M – $30M
F-Prime CapitalCambridge · $3M – $10M
Foresite CapitalWest Hollywood
Premji InvestMenlo Park
RA CapitalBoston
Red Tree VentureSan Diego
Vedanta CapitalNew York
BraidwellreportedStamford
Omega FundsreportedBoston
The Rise FundreportedFort Worth
TPGreported · 2 sourcesSan Francisco

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events
$931.7Mvaluation at IPOSep 2024 · $18.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript | The Motley Foolfool.com · Aug 2026Bicara Therapeutics Strategy and Business Modelumbrex.com · May 2026Bicara Therapeutics prices $150M stock offering | BCAX Stock Newsstocktitan.net · Feb 2026TPG-backed Bicara Therapeutics raises $315 mln in US IPO | Reutersreuters.com · Sep 2024Bicara Therapeutics Raises $165M in Series C Financingfinsmes.com · Dec 2023

Frequently asked questions

What does Bicara Therapeutics do?
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors. The company's lead program, ficerafusp alfa, fuses an EGFR-directed antibody with a TGF-β ligand trap to simultaneously inhibit tumor cell growth and suppress immunosuppressive signaling in the tumor microenvironment, with initial development focused on head and neck squamous cell carcinoma.
Who are Bicara Therapeutics's investors?
Bicara Therapeutics's investors include Aisling Capital, Eight Roads Ventures, F-Prime Capital, Foresite Capital, Premji Invest, RA Capital, Red Tree Venture, Vedanta Capital and 4 more.